Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine (H1) treatment

Next Previous
Trial Profile

A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine (H1) treatment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Acronyms SUNRISE
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 12 Jun 2018 Results (n=136) published in the British Journal of Dermatology.
  • 20 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
  • 18 Sep 2015 New source identified and integrated (ClinicalTrials.gov: NCT02550106)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top